# ANI Pharmaceuticals Inc: overview

ANIP · Nasdaq · CIK 1023024 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/anip.md) · [Financials](/companies/anip/financials.md) · [Filings](/companies/anip/filings.md) · [Insiders](/companies/anip/insiders.md)

Latest reported revenue: [$266.0m](/filings/0001023024-26-000069.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001023024-26-000069).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [148](/filings/0001023024-25-000108.md) | [191 d](/filings/0001023024-26-000014.md) | [197](/filings/0001023024-26-000050.md) | [211](/filings/0001023024-26-000069.md) | [228](/filings/0001023024-25-000108.md) | [247 d](/filings/0001023024-26-000014.md) | [237](/filings/0001023024-26-000050.md) | [266](/filings/0001023024-26-000069.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(13.8%)](/filings/0001023024-25-000108.md) | [(2.3%) d](/filings/0001023024-26-000014.md) | [13.3%](/filings/0001023024-26-000050.md) | [6.6%](/filings/0001023024-26-000069.md) | [15.9%](/filings/0001023024-25-000108.md) | [14.1% d](/filings/0001023024-26-000014.md) | [16.4%](/filings/0001023024-26-000050.md) | [15.2%](/filings/0001023024-26-000069.md) |
| Net margin | % | [(16.3%)](/filings/0001023024-25-000108.md) | [(5.4%) d](/filings/0001023024-26-000014.md) | [8.0%](/filings/0001023024-26-000050.md) | [4.0%](/filings/0001023024-26-000069.md) | [11.7%](/filings/0001023024-25-000108.md) | [11.1% d](/filings/0001023024-26-000014.md) | [12.4%](/filings/0001023024-26-000050.md) | [9.3%](/filings/0001023024-26-000069.md) |
| Diluted EPS | $ per share | [(1.27)](/filings/0001023024-25-000108.md) | not reported | [0.69](/filings/0001023024-26-000050.md) | [0.36](/filings/0001023024-26-000069.md) | [1.13](/filings/0001023024-25-000108.md) | not reported | [1.28](/filings/0001023024-26-000050.md) | [1.05](/filings/0001023024-26-000069.md) |
| Free cash flow | $m | [7.7 d](/filings/0001023024-25-000108.md) | [13.5 d](/filings/0001023024-26-000014.md) | [32.5](/filings/0001023024-26-000050.md) | [71.8 d](/filings/0001023024-26-000069.md) | [38.0 d](/filings/0001023024-25-000108.md) | [29.1 d](/filings/0001023024-26-000014.md) | [52.3](/filings/0001023024-26-000050.md) | [53.6 d](/filings/0001023024-26-000069.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [216](/filings/0001023024-24-000026.md) | [316](/filings/0001023024-25-000015.md) | [487](/filings/0001023024-26-000014.md) | [614](/filings/0001023024-26-000014.md) | [883](/filings/0001023024-26-000014.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(18.4%)](/filings/0001023024-24-000026.md) | [(11.2%)](/filings/0001023024-25-000015.md) | [9.6%](/filings/0001023024-26-000014.md) | [0.1%](/filings/0001023024-26-000014.md) | [12.6%](/filings/0001023024-26-000014.md) |
| Net margin | % | [(19.7%)](/filings/0001023024-24-000026.md) | [(15.1%)](/filings/0001023024-25-000015.md) | [3.9%](/filings/0001023024-26-000014.md) | [(3.0%)](/filings/0001023024-26-000014.md) | [8.9%](/filings/0001023024-26-000014.md) |
| Diluted EPS | $ per share | [(3.40)](/filings/0001023024-24-000026.md) | [(3.05)](/filings/0001023024-25-000015.md) | [0.85](/filings/0001023024-26-000014.md) | [(1.04)](/filings/0001023024-26-000014.md) | [3.32](/filings/0001023024-26-000014.md) |
| Free cash flow | $m | [0.8](/filings/0001023024-24-000026.md) | [(40.1)](/filings/0001023024-25-000015.md) | [110](/filings/0001023024-26-000014.md) | [47.8](/filings/0001023024-26-000014.md) | [171](/filings/0001023024-26-000014.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/anip/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $244.9m | 2,958,646 |  | Added +211,154 |
| [Soleus Capital Management, L.P.](/funds/1802630.md) | 2026-06-30 | $71.8m | 867,760 |  | Added +47,517 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $69.4m | 838,224 |  | Added +15,160 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $68.9m | 831,647 |  | Added +60,060 |
| [TANG CAPITAL MANAGEMENT LLC](/funds/1232621.md) | 2026-06-30 | $58.6m | 707,500 |  | Unchanged |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $51.6m | 623,463 |  | Added +92,273 |
| [AMERICAN CENTURY COMPANIES INC](/funds/748054.md) | 2026-06-30 | $47.6m | 574,474 |  | Added +382,898 |
| [ARROWSTREET CAPITAL, LIMITED PARTNERSHIP](/funds/1164508.md) | 2026-06-30 | $46.5m | 562,016 |  | Reduced −2,344 |
| [Global Alpha Capital Management Ltd.](/funds/1584691.md) | 2026-06-30 | $46.2m | 558,003 |  | Added +196,763 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $44.4m | 536,407 |  | Added +47,206 |

## Recent filings

[All 1,450 filings](/companies/anip/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-24 | 07:01 ET | [8-K](/filings/0001023024-26-000071.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001023024-26-000071 |
| 2026-08-07 | 07:01 ET | [10-Q](/filings/0001023024-26-000069.md) | Quarterly report, period 2026-06-30 | 0001023024-26-000069 |
| 2026-08-07 | 07:00 ET | [8-K](/filings/0001023024-26-000068.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001023024-26-000068 |
| 2026-05-21 | 16:13 ET | [8-K](/filings/0001023024-26-000056.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001023024-26-000056 |
| 2026-05-13 | 08:27 ET | [8-K](/filings/0001023024-26-000054.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001023024-26-000054 |
| 2026-05-08 | 06:58 ET | [10-Q](/filings/0001023024-26-000050.md) | Quarterly report, period 2026-03-31 | 0001023024-26-000050 |
| 2026-05-08 | 06:56 ET | [8-K](/filings/0001023024-26-000049.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001023024-26-000049 |
| 2026-04-09 | 16:12 ET | [DEF 14A](/filings/0001023024-26-000039.md) | Proxy statement, period 2025-12-31 | 0001023024-26-000039 |
| 2026-04-07 | 16:21 ET | [8-K](/filings/0001023024-26-000034.md) | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001023024-26-000034 |
| 2026-03-03 | 07:05 ET | [8-K](/filings/0001023024-26-000017.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001023024-26-000017 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001023024-26-000014.md), filed Feb 27, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/496128f4-a5aa-4c58-8ec9-ec597d4f562f)

## About the filer

- CIK: 1023024
- Tickers: ANIP
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 16:45 ET. No prices; not investment advice.